Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56.3M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
2.42M
-
Shares change
-
+2.42M
-
Total reported value, excl. options
-
$103M
-
Value change
-
+$103M
-
Number of buys
-
35
-
Price
-
$42.51
Significant Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q2 2019
36 filings reported holding QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.42M shares
of 56.3M outstanding shares and own 4.3% of the company stock.
Largest 10 shareholders include SC US (TTGP), LTD. (1.04M shares), Alphabet Inc. (454K shares), VANGUARD GROUP INC (175K shares), BlackRock Inc. (139K shares), MANUFACTURERS LIFE INSURANCE COMPANY, THE (100K shares), FMR LLC (72.5K shares), DAFNA Capital Management LLC (65.4K shares), GEODE CAPITAL MANAGEMENT, LLC (54K shares), OxFORD Asset Management LLP (53K shares), and GOLDMAN SACHS GROUP INC (48.1K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.